Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation
收藏数据链接：
官方服务：
资源简介：
This paper revisits Peltzman (1973) in light of two recent opportunities to quantitatively assess tradeoffs in drug regulation. First, reduced regulatory barriers to drug manufacturing associated with the 2017 reauthorization of Generic Drug User Fee Amendments were followed by significantly more
提供机构：
美国国家经济研究局创建时间：
2021-12-01
